Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation.
about
Erythropoietin or darbepoetin for patients with cancerAssessing the Immunogenicity of BiopharmaceuticalsTen years of biosimilars in Europe: development and evolution of the regulatory pathways.Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility.Regulatory and clinical considerations for biosimilar oncology drugsBiosimilar granulocyte-colony-stimulating factor for healthy donor stem cell mobilization: need we be afraid?Comparative effectiveness and safety of erythropoiesis-stimulating agents (biosimilars vs originators) in clinical practice: a population-based cohort study in Italy.Impact of Guidance on the Prescription Patterns of G-CSFs for the Prevention of Febrile Neutropenia Following Anticancer Chemotherapy: A Population-Based Utilization Study in the Lazio Region.Long-term safety of granulocyte colony-stimulating factor in normal donors: is it all clear?Biosimilar recombinant human erythropoietins ("epoetins") and future erythropoiesis-stimulating treatments.The safety of switching between therapeutic proteins.Clinical safety of biosimilar recombinant human erythropoietins.Long-active granulocyte colony-stimulating factor for peripheral blood hematopoietic progenitor cell mobilization.Chronic inflammatory diseases: do immunological patterns drive the choice of biotechnology drugs? A critical review.Erythropoiesis-stimulating agents in allogeneic and autologous hematopoietic stem cell transplantation.Biosimilars: Hope and concern.Biosimilar infliximab for inflammatory bowel disease: from concepts to clinical practice. Case study illustrated with CT-P13.Is there a reason for concern or is it just hype? - A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars.Healthy donor hematopoietic stem cell mobilization with biosimilar granulocyte-colony-stimulating factor: safety, efficacy, and graft performance.Epoetin Alpha and Epoetin Zeta: A Comparative Study on Stimulation of Angiogenesis and Wound Repair in an Experimental Model of Burn Injury.Biosimilars in 3D: definition, development and differentiationEthical issues and concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilisation of stem cells in normal donors.Plerixafor and Filgrastim XM02 (Tevagastrim) as a first line peripheral blood stem cell mobilisation strategy in patients with multiple myeloma and lymphoma candidated to autologous bone marrow transplantation.Efficacy and safety of biosimilar epoetin alpha in patients with chronic lymphoid neoplasms and chemotherapy-induced anaemia: An observational, retrospective, monocentric analysis.Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years' Experience Gained.Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts.Quality Comparison of Biosimilar and Copy Filgrastim Products with the Innovator ProductThe advent of biosimilar therapies in rheumatology—“O Brave New World”
P2860
Q24202335-A6B06318-F8D4-4525-8D78-7D78D5066DA0Q26751485-6C45FCF8-D1E2-40E9-A0DD-2CA5150FFB51Q33713947-2BDCC90E-0227-4633-A66A-54E9722F0331Q35162053-18B3EE71-611A-474B-8E52-46D4F19E0AF8Q35505833-B54B49D3-1546-4BBE-A8D6-BBCE024A0F50Q35835005-2ED1136C-0A17-4455-BC7C-C139959C7541Q37704338-3A68050B-3C7E-42A0-A1CF-ECB5D72813A3Q37737572-5957F63C-5162-47E0-B4E7-DE0DCF2F90BFQ37996560-601E07B4-5852-436B-A59C-FEF4DE6D5ADCQ37999380-A765C560-E83A-455B-A474-4169058C31E4Q38030980-208DB103-F67C-4BCA-BC58-1D85C328749BQ38033576-B42CDABA-CF65-467E-A032-73A256B3CB9EQ38193590-9B14AB77-DB35-4505-AF11-6A07265A1149Q38201788-CE21CDB0-F67B-419A-9361-F4E205DE0D20Q38260255-E4DF6E5D-516B-450D-8008-99DE3BA07373Q38590668-3FE95676-7F32-491A-B7EC-C810D3C9CEDDQ38591241-CCE58F20-06F8-4220-8E37-1E3D8D523295Q38708927-D707E9CD-1E8D-40FA-8CC6-F659C2112B61Q39385304-F48F84C8-9BFB-4B83-9EE4-504C634C910AQ40766694-5DE2B683-11D7-4C64-92EF-07D3B96B2BF5Q41961612-E76B84FD-0ED8-4623-B5E0-0EDBA7C6A38EQ42343646-A41009A3-15D6-4CA5-8066-4E518E46DA2AQ44894394-253E6884-4249-4F22-AF56-815D6B180BEFQ48088431-91CCE735-B6EB-4DD7-97FA-DCDF39674BBCQ50107702-5C374DBB-E530-4A3D-85F3-44896FF2A2BCQ55212098-6AB42B7C-2FB0-466C-8FC5-B720C030D4E4Q57049370-78B985B4-F709-4347-A833-73B964F12382Q57752047-4F264D6F-1070-4391-B5D7-E19104C9BF85
P2860
Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Key concepts and critical issu ...... r Bone Marrow Transplantation.
@en
Key concepts and critical issu ...... r Bone Marrow Transplantation.
@nl
type
label
Key concepts and critical issu ...... r Bone Marrow Transplantation.
@en
Key concepts and critical issu ...... r Bone Marrow Transplantation.
@nl
prefLabel
Key concepts and critical issu ...... r Bone Marrow Transplantation.
@en
Key concepts and critical issu ...... r Bone Marrow Transplantation.
@nl
P2093
P2860
P50
P1433
P1476
Key concepts and critical issu ...... or Bone Marrow Transplantation
@en
P2093
Fabrizio Pane
Giovanni Barosi
Sante Tura
P2860
P304
P356
10.3324/HAEMATOL.2011.041210
P577
2011-07-01T00:00:00Z